Featured Story

  • GSK, Sanofi join Gates Foundation vaccine R&D initiative

    Vaccine manufacturers are often criticized for investing in shots aimed at high-margin Western markets, while neglecting diseases affecting the developing world. This week, the Bill & Melinda Gates Foundation set up a project to spur development in neglected areas by cutting the financial risk of early research.

Dendreon reportedly seeking buyer for struggling business

In August, a Wall Street analyst placed a headline-grabbing $0 price target on the stock of struggling cancer vaccine manufacturer Dendreon. Now, Dendreon has reportedly hired JP Morgan Chase to find someone who sees more value in the company and is willing to back their belief by acquiring the business.

Vaccines a rare bright spot in Merck's gloomy financials

The layoffs and cuts outlined by Merck earlier this month showed the faith it has in the vaccine unit to drive growth over the coming years. And this week brought fresh data to back its decision, with third-quarter results showing strong demand for vaccines propping up other struggling areas of the firm.

UPDATED: Sanofi makes case for Fluzone superior clinical benefit label

In August, Sanofi gave a first look at eagerly anticipated data from Phase III comparing its high-dose Fluzone vaccine with a standard jab. The data prompted Sanofi to talk up its chances of getting a label for superior efficacy data in people aged over 65, and this week it began making its case.

ACIP recommendation gives Novartis a new growth opportunity

The ACIP decision comes two months after the FDA expanded its label for the meningococcal vaccine. Menveo is now cleared for use in babies aged two months and older, and ACIP has recommended use in infants up to the age of 23 months, but only in certain instances.

Gates Foundation backs Brazilian measles and rubella vaccine

Brazil-based Bio-Manguinhos is working with the Bill & Melinda Gates Foundation to produce a combined measles and rubella vaccine for developing countries in Africa and other regions.


From Our Sister Sites

FierceMarkets Network
  • FierceBiotech
  • FierceBiotechIT
  • FierceBiotechResearch
  • FierceBiomarkers
  • FierceDrugDelivery
  • FierceMedicalDevices
  • FierceVaccines
  • FiercePharma
  • FiercePharmaManufacturing
  • FierceCRO
  • FierceDiagnostics
  • More Fierce Network sites
CardioDx aims higher with revised IPO plans

Diagnostics outfit CardioDx upped the high end of its planned IPO to $92 million and revealed some details about its envisioned offering.

FierceBiotech Research
Fewer NIH grants affected by sequestration than initially projected

NIH has issued an updated fact sheet on the impact of federal sequestration, which totaled nearly $1.6 billion in cuts this year.